Loading data for ABUS — first visit, this takes a few seconds.
Arbutus Biopharma Corporation
5.12 +0.00 (0.00%)
- Capitalisation boursière
- $1.02B
- Volume
- 891K
- Prochaine publication des résultats
- Nov 16, 2026
Arbutus Biopharma Corporation (ABUS) : cours, analyse et données
Valeur intrinsèque
Prévisions des analystes
Prévisions boursières →Derniers résultats
| Signalé | Écart estimé | Changement d’une année sur l’autre | |
|---|---|---|---|
| Chiffre d’affaires | $179.1M | n/a | +10054.54% |
| EPS | -$0,04 | -$0,01 | -500.00% |
Métriques
- Cours acheteur
- 5.1
- Capitalisation boursière
- 1.02B
- Résultat net (ttm)
- 153M
- 0.62
- 0.79
- 6.49
- -31.04
- P/B (ttm)
- 3.92
- P/S (ttm)
- 5.59
- Date des résultats
- Nov 16, 2026
- Cours vendeur
- 6.59
- Volume
- 891,403
- Volume moy. (20D)
- 3,097,398
- Ouverture
- 5.12
- Clôture précédente
- 5.12
- Fourchette du jour
- 5.09 - 5.16
- Intervalle de 52 semaines
- 3.50 - 5.45
- Analyste
- n/a
- Objectif de prix
- n/a
- Dividendes
- n/a
- Date ex-dividende
- n/a
À propos de Arbutus Biopharma Corporation
Voir le profil →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Industrie Biotechnology
Secteur Healthcare
Date d’introduction Jul 26, 2007
Employés 19
Bourse NasdaqGS
Symbole boursier ABUS
Site web https://www.arbutusbio.com